# US 2010/0137146 A1 · Method of Screening Antibacterial Drug Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137146 A1
- Document ID: US20100137146A1
- Status: Published application
- Kind: A1
- Application number: 12/305,523
- Filed: 2007-06-22
- Published: 2010-06-03
- Earliest claimed: 2006-06-22
- Assignees: Temasek Lifesciences Laboratory
- Inventors: Ramanujam Srinivasan; Mohan Balasubramanian; Maki Hori
- Web page: https://patentgrep.com/patent/US20100137146A1

## CPC

- C12Q 1/18: Testing for antimicrobial activity of a material
- G01N 33/9446: {Antibacterials}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compounds are identified simultaneously as having antibiotic activity targeting a specific microbial protein and having no or limited toxicity against eukaryotic cells by expressing the microbial protein in eukaryotic cells by expressing the microbial protein in eukaryotic cells which then are used to screen candidate antibiotic compounds. Preferably, yeast cells such as Schizosaccharomyces pombe are transfected with and express a target bacterial protein such as FtsZ or MreB, optionally as a fusion with a reporter protein, and these transfected cells are used to screen libraries of compounds simultaneously for activity against the bacterial protein and lack of toxicity against the yeast cell.

## Claims

### Claim 1

An in vitro method for identifying antibacterial compounds that have significantly greater toxicity to a specific bacterial protein than to eukaryotic cells, which comprises:
(a) providing a eukaryotic cell culture comprising eukaryotic cells;
(b) transfecting said cells with a gene encoding said bacterial protein;
(c) expressing said bacterial protein in said cells;
(d) screening said transfected eukaryotic cells with at least one candidate antibacterial compound for toxic effects against or inhibition of said bacterial protein and simultaneously assessing said transfected eukaryotic cells for indications of toxicity against eukaryotic cells; and
(e) identifying a compound that exhibits selective toxic effect against said specific bacterial protein.

### Claim 2 (depends on 1)

The method of claim 1 wherein said eukaryotic cells are yeast cells.

### Claim 3 (depends on 2)

The method of claim 2 wherein said yeast cells are Schizosaccharomyces pombe.

### Claim 4 (depends on 1)

The method of claim 1 wherein said eukaryotic cells are mammalian cells.

### Claim 5 (depends on 4)

The method of claim 4 wherein said mammalian cells are normal rat kidney cells.

### Claim 6 (depends on 1)

The method of claim 1 wherein said bacterial protein is selected from the group consisting of FtsZ, MreB and both FtsZ and MreB.

### Claim 7 (depends on 1)

The method of claim 1 wherein said bacterial protein is a fusion with a reporter protein.

### Claim 8 (depends on 7)

The method of claim 7 wherein said reporter protein is Green Fluorescent Protein.

### Claim 9

An antibiotic screening cell culture which comprises an in vitro culture of Schizosaccharomyces pombe that expresses a bacterial target protein selected from the group consisting of FtsZ, MreB, both FtsZ and MreB, and fusions thereof with a reporter protein.

### Claim 10 (depends on 9)

The cell culture of claim 9 wherein said bacterial target protein is a fusion of FtsZ and Green Fluorescent Protein.

### Claim 11 (depends on 9)

The cell culture of claim 9 wherein said bacterial target protein is a fusion of MreB and Green Fluorescent Protein.

### Claim 12

A method of identifying antibacterial target proteins from bacteria, which comprises:
(a) providing d GFP fusion genomic library of a bacterium in a yeast expression vector;
(b) expressing said library in yeast cells;
(c) observing said yeast cells by fluorescence microscopy to identify GFP-labeled proteins of said expressed library that form visible assemblies;
(d) assessing said identified proteins with respect to whether said proteins are essential to cell function of said bacterium; and
(e) identifying proteins that form visible assemblies and are essential to cell function of said bacterium as antibacterial target proteins.

### Claim 13 (depends on 12)

The method of claim 12 wherein said yeast cells are Schizosaccharomyces pombe.
